Loading...

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Videos

Showing 47 results.

CT - 761 Video-1

Efficacy of Talicabtagene Autoleucel in Relapsed/Refractory B-NHL in Complete Response at the Time of Infusion: A Single-Center Study

Sasha Pereira

CT - 844 Video-1

Impact of Structured Mock Runs on Trial Execution: A Comparative Study of Two Cellular Therapy Protocols

Mohamed Iburahim Haja Maideen

IBCL - 1332 Video-1

Phase 3 Results From the EPCORE FL-1 Trial of Epcoritamab (E) With Lenalidomide and Rituximab (R2) versus R2 for Relapsed or Refractory Follicular Lymphoma (R/R FL)

Bradley D. Hunter*

IBCL - 1506 Video-1

Clinically Relevant Subgroup Analysis From the Randomized Phase 3 EPCORE FL-1 Trial: Treatment (Tx) Effect of Epcoritamab (E) With Lenalidomide and Rituximab (R2) in Relapsed/Refractory Follicular Lymphoma (R/R FL)

Bradley Hunter

IBCL - 291 Video-1

Patterns of Treatment Utilization and Sequencing Across Lines of Therapy in Waldenstrφm Macroglobulinemia: Real-World Evidence From the United States

Jorge J Castillo

IBCL - 492 Video-1

Diagnostic Delays and Comparable Response Rates to iMCD-Directed Therapies in Patients With and Without Expert-Confirmed Idiopathic Multicentric Castleman Disease Diagnoses

Larissa Borys

IBCL - 510 Video-1

Clinical Characteristics and Survival Outcomes in Waldenstr?m Macroglobulinemia: An Updated Analysis of 10574 Patients From the SEER Database (1975-2020)

Alamin Mustafa

IBCL - 552 Video-1

Administering Tafasitamab, Lenalidomide and Rituximab for Follicular Lymphoma: a Single Institution Experience From the Phase 3 inMIND Study

Danielle Janiszewski

MCL - 1296 Video-1

Treatment Patterns and Clinical Outcomes Among Patients With Treatment-Naïve and Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) in Community Practice Between 2020 and 2025

Javier Munoz

MCL - 178 Video-1

Clinical Outcomes Among Patients With Relapsed/Refractory Mantle Cell Lymphoma Receiving Zanubrutinib or Acalabrutinib in Real-World Practice in the United States

Javier Munoz

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.